LifeTech Capital, a division of Aurora Capital LLC, is a multi-disciplinary team of investment professionals specializing in serving the unique needs of the Biotech, MedTech and High-Tech industries and investor community. Our institutional research team provides exceptional industry insight into the complex analysis of determining the future value of drugs, devices and companies as well as access to leading key opinion leaders. With international media exposure and public appearances at both scientific and financial events, our institutional research team assists companies and investors in unlocking the value of science. LifeTech Capital’s investment banking team and capital markets team is knowledgeable in both the industry and Wall Street and develops appropriate funding strategies and structures. Our capital markets team has access to over 400 institutional investors plus a broad base of accredited retail investors through both Aurora Capital and investor syndicates. We provide both deal and non-deal road shows in the U.S. and Europe as well as conferences and management one-on-one meetings. LifeTech Capital sets the standard for quality service and performance in the most complex and demanding of market sectors.
Aurora Capital LLC is a boutique investment bank and securities firm founded in 1994. Investment banking is comprised of an experienced team of professionals specializing in the life science sector, which utilizes a rigorous process in the selection of investment ideas and investment banking clients. In addition to in-house expertise and experienced personnel, Aurora retains the services of a network of qualified scientific, medical, and other advisors. On the securities and brokerage side of the business, we are teams of knowledgeable and experienced registered representatives with depth of understanding and broad capabilities to meet the challenges of our customers’ investing needs. For more information visit www.auroracapital.com
The LifeTech Capital Team
Stephen M. Dunn
President LifeTech Capital & Senior Managing Director of Research
Mr. Dunn was previously the Managing Director of Life Sciences Research at Jesup & Lamont, as well as Director of Research for Dawson James Securities and Director of Life Sciences at Cabot Adams venture capital group. He has also held management positions in Business Development, Finance and Operations having worked in over 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter, Coulter, Cordis (Johnson & Johnson), Telectronics (St. Jude Medical) as well as several smaller companies. With over 25 years within the global biomedical industry, Mr. Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, M&A and joint ventures with companies such as GlaxoSmithKline, Pharmacia, Novartis, Bayer, Schering AG, Wyeth, Eli Lilly, Pfizer, Genzyme, Martek Biosciences, Fisher Life Sciences, Becton Dickinson, Idec Pharmaceuticals, Ortho Diagnostics, DakoCytomation, Los Alamos and Sandia National Laboratories, the Mayo Clinic Foundation and the Dana-Farber Institute along with dozens of smaller public and private companies throughout the world. Mr. Dunn is a 5-star biotechnology analyst on StarMine and has appeared in both the financial and scientific media such as The Wall Street Journal, CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The Scientist, BioWorld and many other media outlets. He is also a frequent speaker and panel member for many financial, medical and venture capital events.
E-mail: sdunn@lifetechcapital.com
Sachin R. Kelkar
Managing Director of Investment Banking
Mr. Kelkar has over 12 years of operational, entrepreneurial and finance experience in the technology, financial services and healthcare sectors. Most recently, he was a Vice President in Jesup and Lamont’s corporate finance group helping micro and small cap companies raise capital in the healthcare and clean technology sectors. Prior to that, Sachin spent two years working in Wachovia’s healthcare corporate finance group where he executed a variety of deals including merger and acquisition, initial public offerings, debt capital raises, and private placements. Prior to Wachovia, Mr. Kelkar spent five years at Yodlee as a director of the account management group where he was instrumental in growing the company’s top line over 300% by extracting maximum value from the company’s key financial customer relationships and partnerships. He also worked as an intern both in the product marketing group in Abbott’s HUMIRA® franchise and at Genentech where he worked in the Cell Culture Research and Development group. He holds an MBA from the University of Chicago Booth School of Business, and a BA in Molecular and Cell Biology from the University of California Berkeley.
E-mail: skelkar@lifetechcapital.com
Craig A. Pierson
Managing Director of Investment Banking
Mr. Pierson has over 15 years experience in biotechnology financing as Sr. VP of investment banking at a number of firms such as Gruntal & Co., Janney Montgomery Scott, Dawson James, Jesup & Lamont and Legend Merchant. He has completed numerous transactions for both U.S. and European biotechnology companies with various structures including merchant banking, private equity, debt and private placements as well starting the European Institutional Desk at Dawson James. Mr. Pierson attended the Rochester Institute of Technology for chemical engineering and completed the executive pharmacology program at MIT. He remains active in disease-based charities such as the Joe DiMaggio Children’s Hospital, the Leukemia & Lymphoma Society, the Diabetes Research Institute and the Radiological and Imaging Alliance.
E-mail: cpierson@lifetechcapital.com
The Aurora Capital Team
Jeff Margolis
President Aurora Capital
& Head of Investment Banking
jmargolis@auroracapital.com
Jeff Margolis
President Aurora Capital
& Head of Investment Banking
jmargolis@auroracapital.com